sacituzumab
gilead sciences
['mbc', 'choice i', 'sacituzumab', 'sacitu, govi', 'tropics-02', 'medsir']
second interim analysis results from tropics-02 trial presented by dr. show sacituzumab govitecan vs treatment of physician s choice in pts with et-resistant hr+/her2- mbc, significantly improved os (median, 14.4 vs 11.2 months), orr (21% vs 14%), and qol. #esmo2022 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM